Longevity Peptides: Three Things to Settle Before Adding Them to a Medical Offer
Medical Strategy & Clinical Leadership
MD, PhD in Molecular Diagnostics (Cum Laude), with over 27 years of clinical practice in precision, regenerative, functional, and integrative medicine. She is Chief Scientific Officer at Longevity.Tech.fund and Chief Medical Officer at HealthyLongevity.clinic.
Longevity peptides may soon be easier to buy in the United States. That will not make them better studied.
In October, the Washington Post reported that the administration is preparing a stopgap. It would let compounding pharmacies sell some previously restricted peptides while officials write the rules. Nothing has been announced yet.
What the FDA Committee Decided
In July, the FDA’s Pharmacy Compounding Advisory Committee narrowly recommended six peptides, among them BPC-157, TB-500, and MOTS-c. However, FDA staff scientists opposed all of them. They cited thin clinical data, batch to batch inconsistency, and the risk of immune reactions.
How Thin the Evidence Is
The gap is concrete. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies. Thirty-five were preclinical. The only clinical study was a retrospective series of 12 patients.
Therefore, easier access does not equal better evidence. Physicians, hospital groups, and resort operators asked to add peptides should settle three things first.
First: Evidence Tier, One Peptide at a Time
A GLP-1 drug and BPC-157 share a chemical class, not an evidence base. Consequently, each peptide needs its own review. A team should record the evidence tier for every peptide it considers, before it writes a price list.
Second: Supply and Quality
Insist on a registered manufacturer, a licensed pharmacy, and a prescription. Purity and the label “pharma grade” alone do not provide enough data to judge quality.
Acetate content also matters, because it changes how much active peptide each vial holds. Therefore, ask for a certificate of analysis for every batch that reports both purity and acetate content. “Research use only” vials have no place in a medical offer.
Third: Follow-Up
Informed consent should name the uncertainty. In addition, each patient needs a measurable goal, adverse event reporting, and a date to review or stop. Without these, a peptide offer becomes a product sale, not medicine.
A Simple Peptide Policy for a Medical Team
A written policy keeps the three checks consistent. It should list each peptide the team considers and record its evidence tier. It should name the approved supplier and the batch documents on file. Finally, it should set the consent wording and the review date.
Consequently, every physician applies the same standard, and no peptide enters the offer by accident. In addition, the policy gives the medical director a clear record if a regulator asks questions.
What to Tell Patients
Patients deserve plain language. Explain that a drug on the market and a peptide with little human data are not the same thing. Describe the uncertainty, the goal, and the date when the team will review results. Furthermore, say clearly that the plan can stop if the goal is not met.
Use the Three Checks to Screen Vendors
Hospital groups and resort operators can also use the three checks as a screening tool for vendors. A supplier that cannot produce batch documents fails the second check. A team that cannot name an evidence tier fails the first. Therefore, the checks save time, because they remove weak offers early and leave the physician with a short list.
Access Without Outcome Data Is the Gray Market
Access without outcome data is the gray market with better packaging. In contrast, access with documented outcomes could give this field the evidence it lacks.
Hospital groups and resort operators that document outcomes now will hold that evidence when the rules arrive. As a result, they can show regulators and patients what changed, not just what they sold. Teams that keep this record can also answer a regulator or an insurer quickly. They show what they offered, why they offered it, and what happened next.
Key Takeaways
Easier access to peptides does not create evidence. Teams should settle three points before they add any peptide to an offer. First, record the evidence tier for each peptide. Second, verify supply and quality with batch documents. Third, plan follow-up with consent, a measurable goal, and a stop date. Consequently, the offer stays medical. In contrast, access without outcome data repeats the gray market with better packaging.
Frequently Asked Questions
Why will easier peptide access not mean better evidence?
Access and evidence are separate. FDA staff scientists opposed all six peptides the committee recommended. They cited thin clinical data, batch inconsistency, and immune reaction risk.
How strong is the evidence for BPC-157?
A 2025 systematic review in orthopaedic sports medicine included 36 studies. Thirty-five were preclinical, and the only clinical study was a retrospective series of 12 patients.
What should a medical team check about peptide supply?
Check for a registered manufacturer, a licensed pharmacy, and a prescription. Also request a certificate of analysis for each batch that reports purity and acetate content.
Are "research use only" peptides acceptable in a medical offer?
No. “Research use only” vials have no place in a medical offer.
What follow-up does a peptide offer need?
Consent that names the uncertainty, a measurable goal, adverse event reporting, and a date to review or stop.